[STUDIES ON ANTITUMOR DRUGS. VIII. THE ANTITUMOR EFFECT OF THE ETHYL ESTER OF N-FORMYL-SARCOLYSIN- PHENYLALANINE ON EXPERIMENTAL TUMORS].

The ethyl ester of N-formyl-sarcolycine-phenylalanine (FSPA) was synthetized in this institute. At a daily dosage of 100-200 mg/kg FSPA markedly inhibited the growth of Yoshida ascites sarcoma. The intraperitoneal LD_(50) for mice was 4.5 gm/kg. When the drug was administered orally to normal monkeys at 100 mg/kg daily for 14 days, no change in blood picture or impairment of liver and kidney functions was noted. However, at 200 mg/kg FSPA showed definite inhibitory effect on the bone marrow. This compound has been recommended for clinical trial.